Our Science
LICRA: Ligand Independent Cytokine Receptor Activation​​​
Cytokines have tremendous therapeutic potential but don't last long in the body and can be very dangerous–even deadly.
A number of investigators and biotechnology companies are working to harness the power of cytokines and avoid the serious complications that can occur after administration.
Acensus has filed patents to cover a brand new approach to restore cytokine signaling without the need for receptor surface expression or function, stage of cell cycle or other factors that would normally inhibit cytokine responsiveness. We call it "LICRA."
Therapeutic Areas
By treating effector T cells we can restore the ability of these cells to hunt down and kill cancer. We are currently targeting solid tumor indications such as colon cancer and breast cancer.
​
By treating regulatory T cells we restore the ability of these cells to shut off autoimmune responses. We are currently targeting Type 1 Diabetes and Rheumatoid Arthritis.